For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 29,793,146 | 17,210,548 | ||
| Selling, general and administrative | 23,555,079 | 11,378,520 | ||
| Change in fair value contingent consideration | 1,373,942 | - | ||
| Total costs and expenses | 51,974,283 | 28,589,068 | ||
| Loss from operations | -51,974,283 | -28,589,068 | ||
| Interest income | 3,715,094 | 1,069,182 | ||
| Net loss | -48,259,189 | -27,519,886 | ||
| Basic EPS | -0.49 | -1.16 | ||
| Diluted EPS | -0.49 | -1.16 | ||
| Basic Average Shares | 98,310,190 | 23,712,220 | ||
| Diluted Average Shares | 98,310,190 | 23,712,220 | ||
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)